Bacteria are becoming increasingly resistant to antibiotics. This "race" can lead to a situation where antibiotics will stop ...

MabGenesis, a biotechnology company specializing in antibody drug development, announced on the 24th that it has raised 470 million yen (approximately $3.2 million) in its latest funding round.

BX-004 is under development for the treatment of cystic fibrosis, non-cystic fibrosis bronchiectasis and resistant pseudomonas aeruginosa infections. It is administered as inhalational formulation.

In a new study, Weizmann Institute of Science researchers reveal a bacterial immune system that thwarts the phages’ plot by attaching a small protein molecule to their tails. The components of this ...

Armata Pharmaceuticals (ARMP) announced “encouraging” topline results from its Phase 2 trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary ...

Armata Pharmaceuticals ( (ARMP) ) has issued an announcement.

New research from the University of Guelph will focus on determining if bacteriophages can replace antibiotics to reduce the ...

Dr. Marisa Azad treated a patient using phage therapy, which enlists viruses to fight bacterial infections. An Ottawa ...

Qeen Biotechnologies Inc., a leader in bacteriophage-based solutions, is proud to announce its role in providing ...

Some viruses only infect bacterial cells; they are known as bacteriophages, and they have real potential to defeat antibiotic ...

Winners of UTSA’s annual Innovation Awards were recently announced, in recognition of their substantial contributions to the ...

It is possible to substantially enhance these antibodies’ therapeutic potential via humanization, effectively reducing ...